Webcast Main Sessions and Satellite Symposia
Main Session I: Epigenetic Changes in Acute Leukemias
Sunday, February 22, 2015
- C. Chen, New York: Deciphering the Role of Large Chromosome Deletions in Hematological Malignancies
- Ch. Plass, Heidelberg: Epigenetic Deregulation in Myeloid Malignancies
Main Session II: Characterization of Leukemic Stem Cells
Sunday, February 22, 2015
Special Lecture
Monday, February 23, 2015
Main Session III: Genetic and Molecular Characterization of AML: Novel Markers for Diagnosis and Prognosis
Monday, February 23, 2015
- C. Bloomfield, Columbus: New Molecular Diagnostic Characterization of AML in the 2015 WHO Classification
- M. Levis, Baltimore: Novel FLT3 Inhibitors and Targeted Therapies in AML
- R. Delwel, Rotterdam: Molecular Breakdown of inv(3)/t(3;3) AML with Aberrant EVI1 Expression
- J. P. Maciejewski, Cleveland: Clonal Hierarchy and Diagnostic and Prognostic Impact of Founder Mutations in Myeloid Neoplasms
Main Session IV: Novel Approaches and Targeted Therapies in AML
Monday, February 23, 2015
- B. Huntly, Cambridge: Targeting BET in AML
- M. Andreeff, Houston: Targeting Complementary Bone Marrow Niches in AML
- B.L. Ebert, Boston: Targeting of Ubiquitin Ligases for the Treatment of Hematologic Malignancies
- M. Tallman / E. Stein, New York: IDH2 Inhibitors in Acute Myeloid Leukemias
- R. Stone, Boston: FLT3 Inhibitors in AML Therapy
Main Session VI: Risk Adapted Therapy of AML
Tuesday, February 24, 2015
- G. Roboz, New York: AllianceTrials for AML
- A. Burnett, Cardiff: UK Trials in Acute Myeloid Leukemia
- H. Döhner, Ulm: Molecularly Targeted Therapies - Strategies of the AMLSG
- J. Braess, Regensburg: AMLCG-2008
Main Session VII: Biology and Treatment of APL
Tuesday, February 24, 2015
- F. Lo-Coco, Rome: APL: Should Arsenic-Based Therapy be the New Standard of Care?
- A. Burnett, Cardiff: Attenuated ATO+ATRA is Effective in all APL Risk Groups
- R. Larson, Chicago: Is Maintenance Therapy necessary for APL?
- E. Lengfelder, Mannheim: Acute Promyelocytic Leukemia: High-Risk and Relapsed APL
Satellite Symposium V: New Perspectives in the Treatment of APL (TEVA GmbH)
Tuesday, February 24, 2015